EP 1109921 A4 20020828 - FUSION RECEPTORS SPECIFIC FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
Title (en)
FUSION RECEPTORS SPECIFIC FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF
Title (de)
FÜR DAS PROSTATASPEZIFISCHE MEMBRANANTIGEN SPEZIFISCHE FUSIONSREZEPTOREN UND DEREN VERWENDUNGEN
Title (fr)
RECEPTEURS DE FUSION SPECIFIQUES A L'ANTIGENE PROSTATIQUE SPECIFIQUE MEMBRANAIRE ET SES UTILISATIONS
Publication
Application
Priority
- US 9920349 W 19990903
- US 9913898 P 19980904
Abstract (en)
[origin: WO0014257A1] A fusion receptor composition which is effective to promote a cellular immune response to prostate-specific membrane antigen (PSMA) in vivo when the fusion receptors is expressed by T lymphocytes has the structure: PSMA-scFv: connector: cytoplasmic domain. The PSMA-scFv in this structure is a single chain antibody cloned from the V region genes of a hybridoma specific for PSMA. The connector region is provided to give a spacing between the OSMA-scFv and the cytoplasmic domain, such that both can retain substantial function. A suitable connector is the CD8 hinge, although other connectors of greater or lesser length might be used. The cytoplasmic domain is included to direct the function of the fusion receptor. One exemplary cytoplasmic domain which can be used in the fusion receptor of the invention is a T cell receptor zeta -chain cytoplasmic domain. An expression vector encoding the fusion receptor is transduced into primary T lymphocytes obtained from an individual to be treated. The transduced lymphocytes are returned to the patient where cells expressing the fusion receptor secrete interleukin 2 and proliferate in response to PSMA-positive cells. The resulting cytotoxic lymphocytes specifically lyse cells expressing PSMA and thus can be used to target PSMA-positive tumor cells and neovasculature.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 35/26 (2006.01); A61K 35/76 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC (source: EP)
A61P 35/00 (2017.12); A61P 37/04 (2017.12); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/3069 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C12N 2799/027 (2013.01)
Citation (search report)
- [YD] ALVAREZ-VALLINA L ET AL: "ANTIGEN-SPECIFIC TARGETING OF CD28-MEDIATED T CELL CO-STIMULATION USING CHIMERIC SINGLE-CHAIN ANTIBODY VARIABLE FRAGMENT-CD28 RECEPTORS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 26, no. 10, 1 October 1996 (1996-10-01), pages 2304 - 2309, XP000646504, ISSN: 0014-2980
- [Y] MORITZ D ET AL: "A SPACER REGION BETWEEN THE SINGLE CHAIN ANTIBODY AND THE CD3 KSI-CHAIN DOMAIN OF CHIMERIC T CELL RECEPTOR COMPONENTS IS REQUIRED FOR EFFICIENT LIGAND BINDING AND SIGNALING ACTIVITY", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 2, no. 8, 1 October 1995 (1995-10-01), pages 539 - 546, XP000674790, ISSN: 0969-7128
- [Y] TRAN A-C ET AL: "CHIMERIC DZETA-RECEPTORS DIRECT HUMAN NATURAL KILLER (NK) EFFECTOR FUNCTION TO PERMIT KILLING OF NK-RESISTANT TUMOR CELLS AND HIV-INFECTED T LYMPHOCYTES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 155, no. 2, June 1995 (1995-06-01), pages 1000 - 1009, XP000882943, ISSN: 0022-1767
- See references of WO 0014257A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0014257 A1 20000316; CA 2343156 A1 20000316; EP 1109921 A1 20010627; EP 1109921 A4 20020828; JP 2002524081 A 20020806
DOCDB simple family (application)
US 9920349 W 19990903; CA 2343156 A 19990903; EP 99945508 A 19990903; JP 2000568998 A 19990903